Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
Potassium channel | 1 |
Target- |
Mechanism Bacterial growth inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Potassium channel blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date05 Jul 2024 |
Sponsor / Collaborator |
Start Date04 Jul 2024 |
Sponsor / Collaborator |
Start Date17 Mar 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
9-Propionylmaridomycin | Staphylococcus Aureus Infections More | Preclinical |
NIP-142(Nissan Chemical) ( Potassium channel ) | Arrhythmias, Cardiac More | Preclinical |
AHC-93 ( P-gp x chloride channel ) | Reperfusion Injury More | Pending |
HNS-32 ( VDCCs ) | Arrhythmias, Cardiac More | Pending |
IPS-153 | HIV Infections More | Pending |